Skip to main navigation

close search window

CING | Nasdaq Listed

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

Header Social TwitterLinkedInFacebookYoutube

Header Menu

Company
Pipeline
Partners
Investors
Careers
Press Releases
Cingulate In the News
Contact us

close search window

Search:

search submit button

A man and woman talking

Events & Presentations

Events & Presentations

Presentations

2026 APSARD Poster 686.2 KB

2025 AACAP Presentation 641.4 KB

CINGULATE NMA 2025 Poster 1.5 MB

LD Micro Main Event XVI Presentation

CTx-1301 Psych Congress Presentation 2023 846.1 KB

Past Presentations

2018 APSARD Poster

2020 AACAP Poster

2021 APSARD Poster

CTx-1301 Psych Congress Presentation 2023

CTx-2103 Psych Congress Presentation 2022

2017 AAPS Poster

Events

07 Jan 2025

Cingulate CEO Discusses Safety Data for CTx-1301

Click here for webcast

19 Dec 2024 at 9:00 AM EST

Cingulate CEO Shane Schaffer Discusses Timeline to NDA submission for lead ADHD Asset CTx-1301

Click here for webcast

19 Dec 2024

Cingulate’s Shane Schaffer addresses the most prevalent unmet need in ADHD

Click here for webcast

19 Dec 2024

Cingulate's CEO Shane Schaffer discusses our proprietary Precision Timed Release Technology on Unboxing Biotech

Click here for webcast

17 Dec 2024 at 9:00 AM EST

Cingulate’s Shane Schaffer Joins Big Biz Show for 3-Part Series

Click here for webcast

17 Dec 2024

Dr. Schaffer & Dr. Brams: The Big Biz Show, Part 3

Click here for webcast

17 Dec 2024

Cingulate’s CMO, Dr. Brams, and CEO, Dr. Schaffer, explain how CTx-1301 is designed.

Click here for webcast

19 Nov 2024

CEO Shane Schaffer discusses CING’s $19.5M Increase in Working Capital

Click here for webcast

31 Oct 2024

Revolutionizing ADHD Treatment: Shane Schaffer Discusses Cingulate’s Technology on The Big Biz Show

Click here for webcast

29 Oct 2024

Cingulate On The Path To Commercialization

Click here for webcast

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Next page
Last page

Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301

Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

TwitterLinkedInFacebookYoutube

Contact us

1901 W 47th Place
Kansas City 66205

info@cingulate.com
913-942-2300

© Cingulate^® | PRIVACY POLICY